

## Leslie A. Rylander, Ph.D.

SENIOR CONSULTANT

### CONTACT INFORMATION

---

ToxStrategies, A BlueRidge Life Sciences Company  
Cincinnati, OH 45202  
Phone (513) 549-4965  
[lylander@toxstrategies.com](mailto:lylander@toxstrategies.com)

### PROFESSIONAL PROFILE

---

Dr. Leslie Rylander comes to ToxStrategies' Food and Consumer Products practice following a career of more than three decades with a global manufacturer of consumer, over-the-counter health and beauty products. During the first half of her tenure, she assessed the safety of new ingredients, technologies, and formulations of beauty products (personal cleansing, hair care) and over-the-counter health-care products at a global scale. Subsequently, she helped establish a corporate department responsible for global product safety surveillance and served at an executive level in safety surveillance and analysis. Her most recent work focused on exposures of children to liquid laundry detergent packs—work that she presented to professional organizations in the United States and Europe and that was published in the literature under non-company authorship.<sup>1</sup>

Dr. Rylander was certified in General Toxicology by the American Board of Toxicology from 1990 through 2015.

### EDUCATION AND DEGREES EARNED

---

- 1986 Ph.D., Pharmacology/Toxicology, University of Arizona, Tucson
- 1984 M.S., Toxicology, University of Arizona, Tucson
- 1979 B.S., Biochemistry, Purdue University, West Lafayette, IN

---

<sup>1</sup> Yin S, Colvin J, Behrman A. 2018. Single-use laundry detergent pack exposures in children under 6 years: A prospective study at U.S. poison control centers. *J Emerg Med* 55(3):354–365.

## SELECTED PROFESSIONAL EXPERIENCE

---

### ***Toxicological Risk Assessment***

Assessed the toxicity of surfactants, perfumes, skin care polymers, peptides, and oral care inactive ingredients (whiteners, polymers).

Designed and directed nonclinical studies to assess ingredient and/or product hazard associated with allergenicity (dermal), irritancy (dermal, oral mucosa, and ocular), subchronic dermal exposure, and mutagenicity.

Performed safety assessments associated with dermal, oral, mucosal, and nasal exposure to household cleaning products, personal cleansing products, oral care products, and OTC health-care products.

Designed and directed *in vitro* hazard assessment using skin penetration models.

Designed and directed safety-in-use clinical studies to support marketing of personal care products (bar soaps, facial cleansers, shampoo).

### ***Industrial Hygiene, Product Adulteration, Product Cleaning Validation***

Determined allergenicity (respiratory) associated with polymer handling in manufacturing, including pre-clinical testing and protein analysis.

Assessed acceptable human exposure to manufacturing contaminants in finished products.

Determined acceptable residue of cleaning products on manufacturing equipment.

### ***Global Product Safety Surveillance and Analysis***

Established best practice for globally compliant consumer product safety surveillance (SOPs, procedures, data system upgrade, and training).

Provided technical oversight and guidance for safety signal detection (detection, evaluation, documentation, action plan).

## PUBLISHED WORK

---

Norton JN, Rylander LA, Richards JL. 1995. *In vitro* oral mucosa irritation testing with human cell cultures. *Toxicol In Vitro* 9(1):67–74.

Rylander LA, Gandolfi AJ, Brendel K. 1985. Use of isolated rabbit renal tubules to examine inhibition of organic acid/base transport by toxins. In: Bach PH, Locks EA (eds), *Renal Heterogeneity and Target Organ Toxicity*. New York: John Wiley & Sons, pp. 531–534.

Rylander LA, Gandolfi AJ, Brendel K. 1985. Inhibition of organic acid/base transport in isolated rabbit renal tubules by nephrotoxins. In: *Alternative Methods in Toxicology series, Volume 3*. *In Vitro Toxicol* 1(2):235–247.

Rylander LA, Phelps JS, Gandolfi AJ, Brendel K. 1985. *In vitro* nephrotoxicity: Response of isolated renal tubules to cadmium chloride and dichlorovinylcysteine. *In Vitro Toxicol* 1(2):111–127.

## POSTERS, PRESENTATIONS, AND ABSTRACTS

---

Rylander LA, Behrman A, Vasunia K. In market safety surveillance of laundry detergent using PCC data. Presentation to North American Congress of Clinical Toxicology Annual Meeting, Sept 2016.

- Rylander LA**, Colvin J, Yin S, Behrman A, Vasunia K. Four year trend analysis of childhood exposures to liquid laundry detergent packs. Poster at North American Congress of Clinical Toxicology Annual Meeting, Sept 2016.
- Rylander LA**, Yin S, Colvin J, Stijnties G, Vasunia K. Childhood exposure to single use laundry detergent packs in the US. Poster at European Association of Poison Centres and Clinical Toxicologists, May 2016.
- Rylander LA**. Product vigilance — A competitive advantage. Presentation to Global Beauty Care Band 4+ Offsite, April 2016.
- Rylander LA**, Ernst T. You can't know where you're going if you don't know where you've been. Poster at Mason Business Center World's Fair, Jan 2016.
- Rylander LA**. 3CT and global safety surveillance & analysis — Update on structure and process. Presentation at Singapore Innovation Center, Oct 2015.
- Rylander LA**, Colvin J, Yin S, Behrman A, Vanunia K. Impact of time on market and prevention strategies on accidental childhood exposures to single use laundry detergent packs. Platform presentation, North American Congress of Clinical Toxicology Annual Meeting, Oct 2014.
- Rylander LA**, Colvin J, Behrman A, Yin S, Vanunia K. Triage guidelines and referral patterns associated with single-use laundry product detergent packs. Poster, North American Congress of Clinical Toxicology Annual Meeting, Sept 2013.
- Rylander LA**, Colvin J, Behrman A, Yin S, Vanunia K. First year market safety surveillance data for single-use laundry detergent packs. Poster, North American Congress of Clinical Toxicology Annual Meeting, Sept 2013.
- Rylander LA**, O'Sullivan U. Global safety surveillance & analysis: Regulatory compliance., P&G Global Product Stewardship Capabilities Fair, Aug 2013.
- Rylander LA**, Bjerke D. Olayd: Partnering with PS&RA. Presentation (with D. Bjerke), Product Safety & Regulatory Affairs Department Meeting, Feb 2012.
- Rylander LA**. Integrated product complaint management. Presentation (with Gilday-Weber K), P&G Advanced Compliance Training for Global Personal Health Care Product Supply Leadership Team, Oct 2010.
- Rylander LA**. Leveraging safety surveillance capability towards commercial understanding. Poster (with Ruschman G), P&G Central Functions Town Hall Meeting, Oct 2010.
- Rylander LA**. Integrated product complaint management in a time of enforcement. Presentation, P&G North American PS&RA Symposium Workshop, Oct 2009.
- Rylander LA**. Global adverse event reporting in the age of the immediate communication. Presentation, P&G North American PS&RA Symposium Workshop, Oct 2008.
- Rylander LA**. Human safety basics. Presentation, P&G Latin American Scientific Relations & Technical Relations Symposium, Nov 2007.
- Rylander LA**. Product safety in the consumer product & health care industry. Presentation, P&G North American PS&RA Symposium, Nov 2007.
- Rylander LA**. Reporting process for serious non-prescription drug and medical device related adverse events in the US: A multi-functional effort. Poster, P&G North American PS&RA Symposium, Nov 2007.
- Rylander LA**. Product safety surveillance is good business practice. Presentation, Continuing Education Seminar, sponsored jointly by the Consumer Healthcare Products Association and US Food & Drug Administration, Nov 2005.
- Rylander LA**. Ethics for human testing: Guidelines. Presentation, P&G Clinical Community of Practice Symposium, March 2004.

**Rylander LA.** Environmental science drivers for the health care global business unit. Presentation, P&G Environmental Science Department Meeting, March 2002.

**Rylander Yueh LA,** Phelps JS, Brendel K, Gandolfi AJ. 1986. Rabbit proximal tubule suspensions for the study of early nephrotoxic events [abstract]. *The Toxicologist* 6(1):174.

**Rylander Yueh LA,** Gandolfi AJ, Brendel K. 1984. Inhibition of organic acid/base transport in isolated rabbit renal tubules by nephrotoxins [abstract]. *The Pharmacologist* 26(30):131.

**Rylander Yueh LA,** Carter DE. 1983. The relationship between acrylamide neurotoxicity and neural tissues concentration: Effects of phenobarbital [abstract]. *Toxicol Lett* 18(Suppl 1):158.

**Rylander Yueh LA,** Carter DE. 1982. Tissue deposition of acrylamide in multiply-dosed 5-weeks vs. 11-week male Holtzman rats [abstract]. *The Toxicologist* 2(1):14.